Navigation Links
How immune cells destroy cancer cells - MDC researchers elucidate mechanism
Date:1/17/2012

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments. The researchers showed that both forms of therapy are highly effective against large tumors. However, the T cells not only kill cancer cells they additionally destroy the tumor blood vessel system, thus impeding the supply of nutrients to the tumor. Consequently, quasi as a side effect, "escapee" mutant tumor cells are eradicated that have become resistant to drug-based treatment and are responsible for tumor recurrence. The researchers hope that their insights in defining optimal conditions for T cell therapy may help improve future clinical trials and thus the treatment of cancer patients (Cancer Cell, doi10.1016/j.ccr.2011.10.019)*.

The researchers transplanted tumor cells into mice that express SV40 large T antigen (Tag), the oncogene that is critical for tumor growth. The researchers were thus able to target and inactivate the oncogene using the antibiotic drug doxycycline (dox), which has an effect similar to modern drugs currently in clinical use. Since the oncogene is also present as antigen on the surface of the tumor cells, the researchers were also able to target these tumors with oncogene-specific T cells. Thus, for the first time the effect of the two completely different therapy approaches could be compared directly with each other.

Moreover, a special feature of the study was that the tumors in the mice were large bigger than one centimeter and containing about one billion cancer cells, comparable to clinical-size tumors in patients. Only then, according to the researchers, is the development of the tumor tissue (tumor stroma), which also includes the tumor vasculature, complete. The tumor is then considered "established". The aim of tumor therapy is to kill all cancer cells to prevent the recurrence of cancer disease.

The researchers showed in mice that the tumor is destroyed by the drug-mediated inactivation of the oncogene, but that the tumor vasculature and thus the blood supply of the tumor remains intact. In addition, due to a high mutation rate, some cancer cells become resistant to the drug and quickly generate new tumors despite continual administration of the anti-cancer drug.

Adoptive T-cell therapy, the researchers noted, is more effective in the mice in the long term, because it destroys the blood supply of the tumor. In addition, it evidently intercepts cancer cells that have altered their characteristics via mutations and thus escape drug treatment. In adoptive T-cell therapy, the researchers modulate the cytotoxic T cells (immune cells toxic for the cell) in the test tube in such a way that the T cells recognize certain features on the surface of cancer cells and specifically destroy the tumor cells. Then these primed immune cells are transferred back into the mice. The researchers point out that techniques to produce highly specialized T cells against human tumors have recently been developed following previous studies by Professor Blankenstein's research group. Now it will be important to determine exactly how these immune cells can be used in future clinical trials.

*Oncogene-targeting T cells reject large tumors, while oncogene inactivation selects escape variants in mouse models of cancer


'/>"/>
Contact: bachtler@mdc-berlin.de
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. A genetic accelerator hits the gas on autoimmune diseases
2. Gene Research Sheds Light on Rare Immune Disease
3. Self-regulation of the immune system suppresses defense against cancer
4. Severe Sepsis Can Harm the Immune System
5. Team pinpoints amino acid variation in immune response gene linked with ulcerative colitis
6. Researchers investigate link between autoimmune diseases and wounds that dont heal
7. Pep talk can revive immune cells exhausted by chronic viral infection
8. Penn researchers repair immune system in leukemia patients following chemotherapy
9. Traumatic injury sets off a genomic storm in immune system pathways
10. Autoimmune Woes May Raise Risk for Lung Clots
11. U-M Medical School and MedImmune join forces to accelerate search for new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology: